Increased expression of p62/SQSTM1 in prion diseases and its association with pathogenic prion protein
Citations Over TimeTop 13% of 2014 papers
Abstract
Prion diseases are neurodegenerative disorders characterized by the aggregation of abnormally folded prion protein (PrP(Sc)). In this study, we focused on the mechanism of clearance of PrP(Sc), which remains unclear. p62 is a cytosolic protein known to mediate both the formation and degradation of aggregates of abnormal proteins. The levels of p62 protein increased in prion-infected brains and persistently infected cell cultures. Upon proteasome inhibition, p62 co-localized with PrP(Sc), forming a large aggregate in the perinuclear region, hereafter referred to as PrP(Sc)-aggresome. These aggregates were surrounded with autophagosome marker LC3 and lysosomes in prion-infected cells. Moreover, transient expression of the phosphomimic form of p62, which has enhanced ubiquitin-binding activity, reduced the amount of PrP(Sc) in prion-infected cells, indicating that the activation of p62 could accelerate the clearance of PrP(Sc). Our findings would thus suggest that p62 could be a target for the therapeutic control of prion diseases.
Related Papers
- → P53: Stability from the Ubiquitin–Proteasome System and Specific 26S Proteasome Inhibitors(2022)29 cited
- → Autoregulation of the 26S proteasome by in situ ubiquitination(2014)69 cited
- → HECT ubiquitin ligases as accessory proteins of the plant proteasome(2022)17 cited
- → The Intracellular Localization of the Proteasome(2002)27 cited
- Ubiquitin-like Protein FAT10-mediated Proteasome Degradation(2014)